Retinopathy Team
視網膜病變團隊
Retinopathy Team
視網膜病變團隊
團隊成員
研究亮點
研究成果
團隊成員
團隊成員順序依英文姓名排序
研究亮點
世界衛生組織近年來曾發布首份”世界視力報告”,指出人口老化、生活方式改變、眼科疾病照料不足以及藥物之缺乏是全球視力障礙人數不斷上升的主要因素。2020年全球眼藥市場約367億美金，預估到2028年將增加至600億美金。目前全球預估有1.1億人口有嚴重程度不同的眼睛相關疾病，可見不斷增加的眼科疾病未來將會是人類不可忽略的重大疾病。
本視網膜團隊主要研究方向包括，與視網膜相關的老人黃斑部病變、糖尿病誘發視網膜病變、青光眼及其致病機轉與風險因子。 此外還有、白內障、發炎性眼科疾病、眼腦疾病以及開發早期診斷眼腦相關疾病之生物標記與解決藥物通透與吸收不良的劑型改良等。
我們團隊包括臨床醫師, 生理、藥理、毒理、藥劑以及基礎神經科學研究人員, 我們獲得科技部補助，包括整合型與多項個人型計畫顯示專業與研究能力傑出且受到肯定。
我們期待, 整合各個研究團隊的能量, 能探究更多尚未明瞭的眼科疾病致病機轉以及針對人類最大的眼科疾病需求開發新的治療藥物。
研究成果
發表文章：
1. Wu LH, Cheng YW, Lin FL, Hsu KC, Wang MH, Yen JL, Wang TJ, Lin TE, Liu YC, Huang W-J, Hsiao G, (2024) A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. Biomed Pharmacother. (174):116538.
2. Lin FL, Cheng YW*, Chen LH, Ho JD, Yen JL, Wang MH, Lee TH*, Hsiao G*, (2023). Retinal protection by fungal product Theissen lactone B in a sodium iodate-induced AMD model through targeting retinal pigment epithelial matrix metalloproteinase-9 and microglia activity. Biomedicine & Pharmacotherapy. (158):114138-114148.
3. Chan YJ, Hsiao G, Wan WH, Tsa CH, Kang JJ, Lee YC, Fang TC, Cheng YW, Li CH, (2023). Blue light exposure collapses the inner blood-retinal barrier by accelerating endothelial CLDN5 degradation through the disturbance of GNAZ and the activation of ADAM17. Fluids and Barriers of the CNS. (20):1-20.
4. Fitriana I, Wu GH, Hsu TJ, Chan YJ, Li CH, Lee CC, Hsiao G, Cheng YW, (2023). Activation of aryl hydrocarbon receptor by azatyrosine-phenylbutyric hydroxyamide inhibits progression of diabetic retinopathy mice. Biochemical Pharmacology. (1):1-13.
5. Chan YJ, Liao PL, Tsai CH, Cheng YW, Lin FL, Ho JD, Chen CY, Li CH, (2021). Titanium dioxide nanoparticles impair the inner blood-retinal barrier and retinal electrophysiology through rapid ADAM17activation and claudin-5 degradation. Particle and Fibre Toxicology. (18):1-16.
6. Hsu TJ, Nepali, K, Tsai CH, Lin FL, Hsiao G, Lai, MJ; Cheng YW, (2021). The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production. Molecules. (26):4359–4378.
7. Tsai CH, Fang TC, Liao PL, Liao JW, Chan YJ, Cheng YW, Li CH, (2020). The Powdered Root of Eurycoma longifolia Jack Improves Beta-Cell Number and Pancreatic Islet Performance through PDX1 Induction and Shows Antihyperglycemic Activity in db/db Mice. Nutrients. (12):1-16.
8. Sekar P, Hsiao G, Chen YS, Lin WW, Chan CM, (2023). P2X7 Is Involved in the Mouse Retinal Degeneration via the Coordinated Actions in Different Retinal Cell Types. Antioxidants. (12).
9. Hsueh PJ, Wang MH, Hsiao CJ, Chen CK, Lin FL, 「Huang SH, Yen JL, Tsai PH, Kuo YH, Hsiao G」, (2021).Ergosta-7,9(11),22-trien-3-ol Alleviates Intracerebral Hemorrhage-Induced Brain Injury and BV-2 Microglial Activation. Molecules. (26):1-18.
10. Choo Jackson, Liao CH, Tseng CL, Chen JL, Cheng HC, Liang CL「Hank Juo SH」, (2023).Inhibition of microRNA-328 Increases Ocular Mucin Expression and Conjunctival Goblet Cells. Biomedicines. (11):1-11.
11. Chu YA, Fang HW, Wu YY, Tang YJ, Haieh EH, She YZ「Chang CY,Lin IC,Chen YJ, Liu GS, Tseng CL」, (2023).Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment. International Journal of Nanomedicine. Int J Nanomedicine. 23, (18):1413-1431.
12. Wang JH, Tseng CL, Lin FL, Chen JY, Hsieh EH, Lama S, Chuang YF, Kumar S, Zhu L, McGuinness MY, Hernandez J, Tu L, Wang PY, Liu GS, (2022).Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization. Theranostics. (12):657-674.
13. Liao CH, Tseng CL, Shiun-LL, Chung-LL, Suh-HJ, (2022). MicroRNA Therapy for Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutic. (38):125-132.
14. Wang JH, Lin FL, Chen JY, Zhu LX, Chuang YF, Tu LL, Ma CK, Ling DM, Hewitt AW, Tseng CL, Shah MH, Bui BV, Wijngaarden P van, Dusting G. J., Wang PY, Liu GS., (2022). TAK1 blockade as a therapy for retinal neovascularization. Pharmacol Res. (187):1-14.
15. Tsai CH, Hoang Le Ngoc, Lin CC, Pan LC, Wu CL, Lin IC, Wang PY, Tseng CL*, (2022). Evaluation of Topical and Subconjunctival Injection of Hyaluronic Acid-Coated Nanoparticles for Drug Delivery to Posterior Eye. Pharmaceutics. (14):1-17.
16. Lin IC, Wang YC, YZ Chen YZ, Tang YJ, Chen KH, Tseng CL, (2022). Dry eye syndrome model established in rabbits via mitomycin C injection in the lacrimal gland. Taiwan Journal of Ophthalmology. Taiwan J Ophthalmol. 4;13(1):34-42.
專長：
眼科學
眼科學
林凡立
博士後研究員
蔡季濠
博士後研究員
團隊成員順序依英文姓名排序
世界衛生組織近年來曾發布首份”世界視力報告”,指出人口老化、生活方式改變、眼科疾病照料不足以及藥物之缺乏是全球視力障礙人數不斷上升的主要因素。2020年全球眼藥市場約367億美金，預估到2028年將增加至600億美金。目前全球預估有1.1億人口有嚴重程度不同的眼睛相關疾病，可見不斷增加的眼科疾病未來將會是人類不可忽略的重大疾病。
本視網膜團隊主要研究方向包括，與視網膜相關的老人黃斑部病變、糖尿病誘發視網膜病變、青光眼及其致病機轉與風險因子。 此外還有、白內障、發炎性眼科疾病、眼腦疾病以及開發早期診斷眼腦相關疾病之生物標記與解決藥物通透與吸收不良的劑型改良等。
我們團隊包括臨床醫師, 生理、藥理、毒理、藥劑以及基礎神經科學研究人員, 我們獲得科技部補助，包括整合型與多項個人型計畫顯示專業與研究能力傑出且受到肯定。
我們期待, 整合各個研究團隊的能量, 能探究更多尚未明瞭的眼科疾病致病機轉以及針對人類最大的眼科疾病需求開發新的治療藥物。
本視網膜團隊主要研究方向包括，與視網膜相關的老人黃斑部病變、糖尿病誘發視網膜病變、青光眼及其致病機轉與風險因子。 此外還有、白內障、發炎性眼科疾病、眼腦疾病以及開發早期診斷眼腦相關疾病之生物標記與解決藥物通透與吸收不良的劑型改良等。
我們團隊包括臨床醫師, 生理、藥理、毒理、藥劑以及基礎神經科學研究人員, 我們獲得科技部補助，包括整合型與多項個人型計畫顯示專業與研究能力傑出且受到肯定。
我們期待, 整合各個研究團隊的能量, 能探究更多尚未明瞭的眼科疾病致病機轉以及針對人類最大的眼科疾病需求開發新的治療藥物。
108學年計畫
科技部計畫共4件
國衛院計畫1件
發表文章：
Tsai, C.-H., Li, C.-H., Liao, P.-L., Chang, Y.-W., Cheng, Y.-W., Kang, J.-J. (2020).Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions. Biochimica et Biophysica Acta – Molecular Cell Research,1867(2)
Su, C.-Y., Yeh, L.-K., Lai, C.-C., Li, K.-Y., Tseng, C.-L., Fang, H.-W. (2020).Effects of lysosomal deposition on the friction coefficient of hydrogel contact lenses. Contact Lens and Anterior Eye,43(2) 144-148
Liu, Y.-M., Kuo, C.-N., Liou, J.-P. (2020).Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018). Expert Opinion on Therapeutic Patents,
Wu, W.-C., Liu, Y.-M., Lin, M.-H., Liao, Y.-H., Lai, M.-J., Chuang, H.-Y., Hung, T.-Y., Chen, C.-H., Liou, J.-P. (2020).Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158)). European Journal of Medicinal Chemistry,196
Su, C.-Y., Yeh, L.-K., Lai, C.-C., Dubuisson, M., Tsao, Y.-F., Tseng, C.-L., Fang, H.-W. (2020).The bio-tribological effect of poly-gamma-glutamic acid in the lysozyme-ionic contact lens system. Polymers,12(1)
Wu, W.-C., Liu, Y.-M., Lin, M.-H., Liao, Y.-H., Lai, M.-J., Chuang, H.-Y., Hung, T.-Y., Chen, C.-H., Liou, J.-P. (2020).Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. European Journal of Medicinal Chemistry,192
科技部計畫共4件
國衛院計畫1件
發表文章：
Tsai, C.-H., Li, C.-H., Liao, P.-L., Chang, Y.-W., Cheng, Y.-W., Kang, J.-J. (2020).Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions. Biochimica et Biophysica Acta – Molecular Cell Research,1867(2)
Su, C.-Y., Yeh, L.-K., Lai, C.-C., Li, K.-Y., Tseng, C.-L., Fang, H.-W. (2020).Effects of lysosomal deposition on the friction coefficient of hydrogel contact lenses. Contact Lens and Anterior Eye,43(2) 144-148
Liu, Y.-M., Kuo, C.-N., Liou, J.-P. (2020).Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018). Expert Opinion on Therapeutic Patents,
Wu, W.-C., Liu, Y.-M., Lin, M.-H., Liao, Y.-H., Lai, M.-J., Chuang, H.-Y., Hung, T.-Y., Chen, C.-H., Liou, J.-P. (2020).Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158)). European Journal of Medicinal Chemistry,196
Su, C.-Y., Yeh, L.-K., Lai, C.-C., Dubuisson, M., Tsao, Y.-F., Tseng, C.-L., Fang, H.-W. (2020).The bio-tribological effect of poly-gamma-glutamic acid in the lysozyme-ionic contact lens system. Polymers,12(1)
Wu, W.-C., Liu, Y.-M., Lin, M.-H., Liao, Y.-H., Lai, M.-J., Chuang, H.-Y., Hung, T.-Y., Chen, C.-H., Liou, J.-P. (2020).Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. European Journal of Medicinal Chemistry,192
大腦與意識團隊
Brain and Consciousness Team
腦創傷研究團隊
Trauma Brain Injury Team
血小板生醫工程療法團隊
Platelet neurotrophins for neurorestorative biotherapy
